project id: TCGA-UCEC; case submitter id: TCGA-KP-A3VZ; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.3; rna integrity number: 8.6; age at index: 69; days to birth: -25366; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1941; age at diagnosis: 25366; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 722.0; figo stage: Stage IV; icd 10 code: C54.1; last known disease status: not reported; morphology: 8441/3; primary diagnosis: Serous cystadenocarcinoma, NOS; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: Not Reported; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 633; initial weight: 200.0; sample id: f73c1ce5-2813-45b2-951f-8ab539b32988; sample submitter id: TCGA-KP-A3VZ-01A; portion id: 05af429d-e995-4941-9ccc-05ee82c41f6d; portion submitter id: TCGA-KP-A3VZ-01A-11; slide id: 03e30840-a2f5-4309-97d1-8b6a3e2d7a7b; slide submitter id: TCGA-KP-A3VZ-01A-01-TSA; percent lymphocyte infiltration: 60.0; percent monocyte infiltration: 20.0; percent necrosis: 5.0; percent neutrophil infiltration: 10.0; percent normal cells: 0.0; percent stromal cells: 5.0; percent tumor cells: 90.0; percent tumor nuclei: 90.0; section location: TOP;